Market Closed - London S.E. 09:05:07 15/07/2024 pm IST 5-day change 1st Jan Change
3.68 GBX +31.43% Intraday chart for genedrive plc +113.33% -54.71%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
EARNINGS AND TRADING: Genedrive in FDA boost; Bango revenue rises AN
Burberry and miners hit FTSE but New York shines AN
AIM WINNERS & LOSERS: Destiny Pharma falls on plans to go private AN
Genedrive Secures US FDA Breakthrough Device Designation for Rapid Hearing Loss Test MT
Genedrive plc Receives Breakthrough Device Designation from the U.S. Food and Drug Administration CI
EARNINGS AND TRADING: Fenikso in profit; Tate & Lyle completes sale AN
Genedrive Conditionally Raises GBP6 Million via Fundraising MT
FTSE 100 stumbles as rain dampens retail sales AN
Genedrive Wins Initial UK Orders for Hearing Loss Test for Infants MT
FTSE 100 in red as UK election heats up AN
Genedrive announces orders for testing kit worth over GBP100,000 AN
AIM WINNERS & LOSERS: Kinovo rises as results ahead of expectations AN
Genedrive plc Receives Initial Orders of the Genedrive MT-RNR1 Products for New Sites in the UK CI
CVS sells Dutch and Irish loss-making businesses AN
Genedrive Raises GBP2 Million via Share Placing MT
Genedrive completes placing portion of GBP6 million raise AN
AIM WINNERS & LOSERS: Polarean wins deal; Genedrive completes placing AN
Molecular Diagnostics Company Genedrive Seeks GBP8 Million Equity Raise MT
Genedrive aims to raise at least GBP6 million in share offer AN
Genedrive enters clinical trial deal in US for MT-RNR1 US approval AN
FTSE 100 up thanks to US economic data AN
Genedrive shares surge as UK's NICE backs test for ischaemic stroke AN
AIM WINNERS & LOSERS: UK NICE backs Genedrive test; Corero renews deal AN
Genedrive's Test Receives Draft Recommendation from UK's NICE MT
EARNINGS AND TRADING: 888 advances US exit; Arrow ups reserve estimate AN
Chart genedrive plc
More charts
genedrive plc is a United Kingdom-based pharmacogenetic testing company. The Company is engaged in developing and commercializing a rapid, versatile, simple to use and robust point-of-need pharmacogenetic platform for the diagnosis of genetic variations. The Company’s products include Genedrive MT-RNR1 ID Kit, Genedrive System, and Genedrive CYP2C19 ID Kit. The Company’s flagship product Genedrive MT-RNR1 ID Kit is a single-use disposable cartridge that circumvents the requirement for cold chain logistics by providing temperature stable reagent test kits for use on their proprietary test platform. The Genedrive System is a rapid thermocycler and signal detection system, enabling PCR and isothermal based amplification techniques. It is a semi- automated system used for qualitative in vitro molecular diagnostic tests. Its Genedrive CYP2C19 ID Kit Molecular point-of-care test for rapid CYP2C19 genotyping in time-critical emergency care settings.
More about the company

Chiffre d''affaires - Rate of surprise

  1. Stock Market
  2. Equities
  3. EHP Stock
  4. News genedrive plc
  5. Genedrive Secures US FDA Breakthrough Device Designation for Rapid Hearing Loss Test